New pill targets rare genetic cancers in first human trial
Disease control
Ongoing
This early-stage study tests an experimental oral drug, APS03118, in adults with advanced solid tumors that have specific RET gene mutations or fusions. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 108 participants will…
Phase: PHASE1 • Sponsor: Applied Pharmaceutical Science, Inc. • Aim: Disease control
Last updated May 17, 2026 14:57 UTC